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Understanding the T cell immune response in SARS
coronavirus infection
Hsueh-Ling Janice Oh1,2, Samuel Ken-En Gan3, Antonio Bertoletti4,5,6 and Yee-Joo Tan2,7
The severe acute respiratory syndrome (SARS) epidemic started in late 2002 and swiftly spread across 5 continents with a mortality
rate of around 10%. Although the epidemic was eventually controlled through the implementation of strict quarantinemeasures, there
continues a need to investigate the SARS coronavirus (SARS-CoV) and develop interventions should it re-emerge. Numerous studies
have shown that neutralizing antibodies against the virus can be found in patients infectedwith SARS-CoVwithin days upon the onset of
illness and lasting up to several months. In contrast, there is little data on the kinetics of T cell responses during SARS-CoV infection
and little is known about their role in the recovery process. However, recent studies in mice suggest the importance of T cells in viral
clearance during SARS-CoV infection. Moreover, a growing number of studies have investigated the memory T cell responses in
recovered SARS patients. This review covers the available literature on the emerging importance of T cell responses in SARS-CoV
infection, particularly on the mapping of cytotoxic T lymphocyte (CTL) epitopes, longevity, polyfunctionality and human leukocyte
antigen (HLA) association as well as their potential implications on treatment and vaccine development.
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INTRODUCTION
Severe acute respiratory syndrome (SARS) first emerged in
Guangdong, China in late 20021 and infected more than 8000 people
in 29 countries across 5 continents.2 According to the World Health
Organization (WHO), the fatality rate of the SARS outbreak was esti-
mated to be 9.6%. Of those infected, healthcare workers and care-
takers accounted for the majority. The SARS epidemic was officially
controlled by July 2003 after the implementation of strict isolation of
patients. Sometime into the epidemic, a novel coronavirus, the SARS
coronavirus (SARS-CoV), was identified as the causative agent.3–5
Molecular epidemiology showed that at least two strains of SARS-
CoV infected the patients in Hong Kong,6 suggesting that the virus
had jumped from animal sources to humans on two separate occa-
sions. Later in 2005, reports from two laboratories identified a virus
resident in Chinese horseshoe bats that is genetically similar to the
human SARS-CoV, pinpointing the horseshoe bat to be a likely
natural reservoir of the SARS-CoV.7,8 If this is indeed the case, a re-
emergence of SARS-CoV cannot be ruled out.
Coronaviruses are a diverse group of large, enveloped positive-
stranded RNA viruses in the order Nilovirales, family Coronavi-
ridae, and genus Coronavirus. Typically, they cause respiratory and
enteric diseases in humans and animals. Using the open reading frame
(ORF) 1a sequences, SARS-CoV was categorized as a subgroup of the
group II coronaviruses.9 The 30 kb poly-adenylated positive-stranded
RNA genome10,11 has an genomic organization typical of a corona-
virus where the first two ORFs (1a and 1b) encode the viral replicase
that requires processing by the viral cysteine proteinases to yield the
functional membrane-bound replicase complex and a group of 16
non-structural proteins (NSP).12 Although some functions of these
NSPs have been investigated and known, there are many others that
still require further characterization (reviewed by Cheng et al.13).
The SARS-CoV genome encodes four structural proteins: spike (S),
envelope (E), membrane (M) and nucleocaspid (N). In addition, a set
of unique accessory proteins (namely ORF 3a, 3b, 6, 7a, 7b, 8a, 8b and
9b) is also found. Functionally, the N protein packs the RNA into a
helical nucleocapsid; while the S protein forms the characteristic pro-
jections on the virion surface for the attachment and entry into the
host cells; and together, N,M and E control the assembly of the virion.
At present, no significant homology has been found for the accessory
proteins to the viral proteins of other coronaviruses; in fact, they were
found to be dispensable for virus replication in cell culture despite
contributing to viral pathogenesis.14,15
Neutralizing antibodies against SARS-CoV found in patients and
animals infected with SARS-CoV block viral entry by binding to the
S glycoprotein.16 Besides the humoral response, the role of T cells
in viral infections has been known to be just as important. Whilst
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neutralizing antibodies can prevent viral entry, the body also requires
SARS-CoV specific CD41 T helper cells for the development of these
specific antibodies. Similarly, CD81 cytotoxic T cells are important for
the recognition and killing of infected cells, particularly in the lungs of
infected individuals. Despite the increasing number of reports that
investigated memory CD41 and CD81 T cell responses in recovered
SARS patients, there is a lack of data that describes the kinetics of the
T cell response during a SARS-CoV infection. This reviewwill focus on
the memory T cell studies and its possible implications on treatment
and vaccine development. For easy reference, all the T cell epitopes
identified are summarized in Table 1.
CHARACTERIZATION OF T CELL EPITOPES IN THE SPIKE (S)
GLYCOPROTEIN
Amongst the SARS-CoV structural proteins, the S protein has been
found to elicit neutralizing antibodies17,18 with its major immuno-
dominant epitope found between residues 441 to 700. Using an online
database and with verification from T2 binding assays, the first two
HLA-A*02:01-restricted T cell epitopes (S1203–1211 and S978–986)
were identified in the S protein of SARS-CoV.19 They were immuno-
genic and elicited high IFNc-specific T cell response in patients who
have recovered from SARS. In comparison, the homologous peptide
from HCoV229e did not elicit a significant response. A third CTL
epitope, S1167–1175 (also known as SSp-1) was reported shortly after
by another group.20 This peptide was able to induce CTL response in
HLA-A*02:01 transgenic mice immunized with peptide loaded dend-
ritic cells (DCs). At the same time, they were able to generate peptide-
specific CD81 CTL in peripheral blood mononuclear cells (PBMCs)
from healthy human donor. The same group also showed that heat
inactivated SARS-CoV particles elicited CTL response to all three S
epitopes (SSp-1, S978 and S1202) in patients’ PBMCs one year post-
infection.21 Interestingly, 5 healthy individuals without contact his-
tory with SARS-CoV also exhibited SSp-1-specific responses in their
PBMCs but exhibited lower cytotoxic activity and cytokine release
when compared to the recovered SARS patients.
Other T cell epitopes identified include S787–795, S1042–1050
(found in the S2 domain) and S411–420 (P15) (found in the S1
domain) .22,23 These epitopes were found to be immunogenic and able
to induce strong IFNc production from PBMCs of recovered SARS
patients. At the same time, HLA-A*02:01 transgenic mice immunized
with DNA vaccines encoding the S protein were able to induce sig-
nificant peptide-specific response.24 In this study, the HLA-A*02:01
restricted epitope S958–966 (also known as Sp8), first identified based
on HLA-A*02:01 binding peptide and proteosomal cleavage predic-
tion systems, was found capable of inducing specific CTLs in the
PBMCs of healthy individuals as well as in transgenic mice immunized
with S DNA vaccine.24 This suggests that there may already be
SARS-CoV-specific CTL precursor cells within the T-cell repertoire
of healthy individuals.
Animal studies using mice primed intramuscularly with S DNA
vaccine and boosted with subcutaneous HLA-A*02:01 restricted pep-
tides25 or with the S DNA vaccine alone26 elicited antigen-specific
CD81 T cell responses. In fact, one recent study showed that prime-
boost immunization of transgenic mice with 5 of the HLA-A*02:01 S
peptides together with CpG oligodeoxynucleotide (ODN) could sig-
nificantly enhance the frequency of peptide-specific CD81 T cells.27
Taken together, the S protein is not only capable of inducing neu-
tralizing antibodies but also contains several immunogenic T cell epi-
topes. Some of these epitopes found in either the S1 or S2 domain of
the protein should therefore be considered during SARS-CoV vaccine
development.
CHARACTERIZATION OF T CELL EPITOPES IN THE
NUCLEOCAPSID (N) PROTEIN
Besides the S glycoprotein, persistently high levels of anti-N protein
antibodies and T cell responses were also found in the SARS-recovered
individuals 2 years post-infection.28,29 For other coronaviruses, some
protective effects were found to be conferred through N-specific
CD81 T cells.30,31 Using a similar approach of HLA peptide binding
prediction algorithm with validation from T2-cell binding assay, Tsao
Table 1 Summary of T cell epitopes found in the SARS-CoV
Protein Amino acid position HLA restriction Identification References
Spike 1203 to 1211 HLA-A*02:01 Human PBMCs 19
Spike 978 to 986 HLA-A*02:01 Human PBMCs 19
Spike 1167 to 1175 HLA-A*02:01 Transgenic mouse and verified in human PBMCs 20
Spike 787 to 795 HLA-A*02:01 Human PBMCs 22
Spike 1042 to 1050 HLA-A*02:01 Human PBMCs 22
Spike 411 to 420 HLA-A*02:01 Human PBMCs 23
Spike 958 to 966 HLA-A*02:01 Transgenic mouse and verified in human PBMCs 24
Nucleocapsid 223 to 231 HLA-A*02:01 Transgenic mouse 22
Nucleocapsid 227 to 235 HLA-A*02:01 Transgenic mouse 22
Nucleocapsid 317 to 325 HLA-A*02:01 Transgenic mouse and verified in human PBMCs 22
Nucleocapsid 331 to 347 HLA-A*02:01 Human PBMCs 28
Nucleocapsid 346 to 362 HLA-A*02:01 Human PBMCs 28
Nucleocapsid 211 to 235 HLA-A*02:01 Human PBMCs 32
Nucleocapsid 330 to 354 HLA-A*02:01 Human PBMCs 32
Nucleocapsid 216 to 225 HLA-B*40:01 Human PBMCs 33, 34
Membrane 21 to 44 ND Human PBMCs 41
Membrane 65 to 91 ND Human PBMCs 41
Membrane 117 to 140 ND Human PBMCs 41
Membrane 200 to 220 ND Human PBMCs 41
Membrane 146 to 160 ND Human PBMCs 34
3a 36 to 50 ND Human PBMCs 34
3a 6 to 20 HLA-B*58:01 Human PBMCs Unpublished
*ND indicates not determined.
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et al. identified several HLA-A*02:01 restricted epitopes in the N
protein (peptide N223–231, N227–235 and N317–325) and showed
that they could induce specific CTL responses in transgenic mice
immunized with N proteins or peptides with CpG ODN.22 In addi-
tion, peptide N317–325 was able to stimulate the recall of CD81 T cell
response in PBMCs of recovered SARS patients.
There had been numerous attempts to screen for CTL epitopes in
the N protein through the use of overlapping peptides spanning the
entire N protein. One such study that used PBMCs from recovered
SARS patients 2 years post-infection has revealed that themajor domi-
nant antigenic site of the N protein lies in the C-terminal region
(amino acids 331 to 362). At least 2 different T cell epitopes (N331–
347 and N346–362) have been found in this region when the PBMCs
were stimulated with a pool of 57 overlapping N peptides in vitro,
followed by IFNc Enzyme-linked immunosorbent spot (ELISPOT)
assay.28 Using the same approach, another group identified 2 potential
CTL epitopes at positionsN211–235 andN330–354 in theNprotein.32
More recently, we also identified the same dominant response (N216–
230) in SARS-recovered patients 6 years post-infection.33 This res-
ponse was observed in 19% [3/16] of our cohort of recovered SARS
patients. Similarly, a comprehensive study of T cell responses against
all the SARS-CoV proteins conducted by Li et al. showed that 11% of
their SARS subjects gave positive T cell responses against peptide
N211–225, and it was identified as the most recognized epitope in
theNprotein.34 Exact epitopemapping by our group further indicated
that the CTL epitope was a 10 mer (N216–225) restricted by HLA-
B*40:01 and that PBMCs from healthy individuals can be transduced
to become N peptide-specific T cells.33
In one of the first animal studies conducted inmonkeys, adenoviral-
based vectors were used to test the efficacy of the S, M and N
proteins.35 The monkeys were injected intramuscularly with adeno-
viral-based vectors that expressed codon-optimized S1 domain, M
and N proteins. The S1 domain of the S protein was found to induce
strong humoral response, while the N protein elicited high frequency
of IFNc-producing T cells as determined using N peptides as the
antigen in the ELISPOT assay. This was the first indication that the
N protein could be a good vaccine candidate for cell-mediated T cell
response. This phenomenon was also found in mice where DNA vac-
cines encoding the N protein elicited good T cell responses.36–39 C3H/
Hemice intramuscularly immunized withNprotein pcDNA-fn vector
showed both high antibody titre and CTL activity after 3 injections;36
and using Balb/c mice, two other groups showed that DNA vaccines
encodingN protein alone could elicit T cell proliferation, IFNc release,
delayed-type hypersensitivity (DTH) and in vivo cytotoxic T cell acti-
vity.37,38 Further experiments reported enhanced T cell response when
calreticulin (CRT)-linked DNA vaccine was used39 or DNA vaccina-
tion was performed with the addition of a chemical adjuvant levami-
sole.38 Synthetic N peptides coupled to the surface of liposomes were
also reported to enhance T cell response.40 These synthetic N peptides
not only induced CTL response, but the mice were also able to clear
vaccinia virus-expressing SARS-CoV epitopes when challenged.40
In summary, several different studies have identified immunogenic
regions in amino acids 211 to 362 of the N protein to contain T cell
epitopes. However, to date, the only epitope characterized in detail is
the 10-mer epitope (N216–225) which is restricted byHLA-B*40:01.33
CHARACTERIZATION OF T CELL EPITOPES IN OTHER
SARS-COV PROTEINS
There are very few studies of T cell response to other SARS-CoV
proteins. Nonetheless, animal studies usingDNA vaccines suggest that
theM proteinmay induce T cell response, albeit to a lesser degree than
the S and N proteins.38 Yang et al. demonstrated that it was possible
to induce recall T cell response from the PBMCs of SARS patients
who have recovered for more than 1 year by using overlapping pep-
tides spanning the entire M protein.41 In this study, four human T cell
immunodominant peptides, M21–44, M65–91, M117–140 and
M200–220, were subsequently identified. Similarly, Li et al. also
reported that 9% of their SARS subjects had T cell response against
the M peptide region, M146–160.34 The largest accessory protein of
SARS-CoV is the 3a protein of 274 amino acids. However, other than
Li et al.’s report, there had been no demonstration of T cell responses
against this protein. The 3a protein peptide 3a36–50 was one of the
three most frequently recognized T cell epitopes identified in their
study.34 Similar to the results reported by Li et al. our data showed
that the 3a protein peptide 3a6-20 was able to elicit both CD81 and
CD41 responses.33 Interestingly, mice immunized with 3a DNA vac-
cine were shown to have high levels of humoral response as well as Th1
response.42 These observations indicated that the accessory 3a protein
is immunogenic and able to induce T cell response.
Although T cell response could be observed for the M protein,
current studies seem to suggest that the 3a protein is more immuno-
genic in comparison, and T cell epitopes identified in it may play an
important role in recovery from a primary SARS-CoV infection and in
vaccine development.
LONGEVITY AND PHENOTYPE OF CD41 AND CD81 T CELL
RESPONSES
To date, there is only one study that investigated T cell response
against whole SARS-CoV in humans.34 In this study, PBMCs
from 1-year post-infected patients showed T cell response to eight
(replicase, S, N, E, M, 3a, 3b, and 9b) out of the fourteen SARS-CoV
proteins when tested using overlapping peptides spanning the entire
SARS-CoV genome. Of the 70% of T cell responses elicited
against the structural proteins, the S protein induced the most
dominant responses (41%). In fact, the three most commonly
recognized T cell epitope were that of one found in 3a, and the
other two in the S protein (S435–451 and S633–650). The latter were
not reported in the other studies. Although both CD41 and CD81
T cell responses were observed in the study, the frequency and mag-
nitude of the CD81 T cell responses were greater than the CD41 T cell
responses. However, the CD41 and CD81 T cells were found to have
similar central memory phenotypes (CD271 and CD45RO1). A sepa-
rate study by Peng et al. showed that the N-specific CD41 T cells
had central memory (CD45RA2 CCR71 CD62L2), whereas most
of the CD81 T cells had effector memory (CD45RA1 CCR72
CD62L2) phenotype.28 Similar observations were made with the
M-specific CD41 and CD81 T cells,41 whilst the S-specific CD81
T cells were reported to have effector memory (CD45RA1 CCR72
CD62L2) phenotype.21
Using peptides in the four SARS-CoV structural proteins, an ana-
lysis of the memory T cell response in recovered SARS patients four
years post-infection revealed that both CD41 and CD81 T cells pro-
duced IFNc.43 In support of Li et al.’s study,34 Fan et al. also found that
CD41memory T cells produce IL-2, TNFa and IFNc, with the excep-
tion of one patient.43 It was also observed that S peptides induced the
highest percentages of IFNc producing cells. Interestingly, the fre-
quency of these polyfunctional CD41 T cells (T cells producing mul-
tiple cytokines) was higher in the individuals with severe SARS
infection than inmoderately severe patients.34 On the other hand, this
difference between moderate severe and severe patients was
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not observed with the CD81 T cells which produced mainly IFNc.
Nonetheless, a proportion of the CD81 T cells were found to produce
TNFa and degranulate (with the detection of CD107a).
Since polyfunctional T cells were associated with better control of
human immunodeficiency virus (HIV) infection and vaccination effi-
cacy,44,45 we further characterized the cytokine profile of the SARS-
specific T cells in our recent study.33 A summary of our findings is
shown in Figure 1.We have observed that themajority of CD41T cells
produced IFNc, IL-2, and TNFa, with a small percentage of the
cells also simultaneously producing inflammatory cytokines such as
macrophage inflammatory protein (MIP) 1a, MIP 1b and granulo-
cyte-macrophage colony-stimulating factor (GM-CSF). Of these,
the majority of the CD81 T cells produced IFNc, TNFa, MIP 1a or
MIP 1b alone or in combination. Only a small percentage produced
IFNc, IL-2, and TNFa. Moving forward, we cloned the a and b T cell
receptor (TCR) chains of one immunodominant CTL epitope in the N
protein (amino acid 216 to 225) from the SARS-CoV specific CD81 T
cells and used them to redirect the specificity of lymphocytes of
healthy subjects lacking SARS-CoV specific memory T cells. These
TCR-redirected T cells were found to possess a cytokine production
profile similar to SARS-CoV specific memory CD81 T cells in recov-
ered SARS patients (as mentioned above). Thus we proposed that
these T cells may be potential therapeutic treatments for this life
threatening infection.
Despite the numerous reports describing the elevation of inflam-
matory cytokines in primary infected patients (reviewed by Zhu
et al.46), it is not known if these cytokines are beneficial or contribute
to the pathogenicity of the infection. Moreover, there is currently no
report confirming the protective effect of T cells during a primary
SARS-CoV infection in humans. In fact, research in this area is ham-
pered by the lack of systematic sample collection during the 2003 SARS
outbreak which lasted for a relatively short period of, 16 weeks. Since
there is no second major outbreak of SARS, the protective effect of
memory T cell response in recovered SARS patients is not known.
Nevertheless, the phenotype and cytokine profile of the T cells in these
recovered individuals indicate the possible protective effect of T cell
response in the initial infection or during any subsequent infections.
HLA ASSOCIATION
The association of certain HLA genotypes with increased resistance or
the ability to clear viral infections have been reported in hepatitis C
virus (HCV) and human papillomavirus studies.47–50 Although earlier
studies done on SARS patients fromTaiwan andHongKong suggested
that the HLA-B, HLA-Cw and HLA-DR alleles were highly associated
with SARS infection and disease development,51–53 further investiga-
tion is required. Of these literature, SARS individuals from Hong
Kong showed that HLA-B*07:03 and HLA-DR*03:01 conferred
factors for susceptibility and resistance to SARS infection, respec-
tively.53 In agreement with this, a study on a Taiwanese cohort of
SARS patients found that both HLA-Cw*15:02 and HLA-DR*03:01
were associated with resistance to SARS infection.54 These observa-
tions suggested the important role of HLA-DR*03:01 in viral disease
progression through enhancing the function of CD41 T helper cells.
Similarly, we observed that the CD81 T cell responses against both the
N and 3a proteins were all restricted by HLA-B subtype (unpublished
data), thus pointing to the possible role of HLA-B subtypes in viral
immunity. Among the HLA class I genes, HLA-B is known to be the
most polymorphic,55 and was associated in protective roles against the
HIV,56–58 HCV59 and acute influenza infections.60
CONCLUSION
Currently, no antiviral therapy has yet been proven useful for SARS.
Attempts to test potential anti-SARS agents using antiviral antibodies,
entry inhibitors, proteinase inhibitors, calpain inhibitors, ribavirin
(nucleoside analogues), interferons, and short interfering RNAs were
riddled with contradictory reports from different laboratories. The
lack of clinical trials also prevented the reaching of a conclusive agree-
ment for effective anti-SARS strategies (reviewed by Weiss et al.61).
Nevertheless, human convalescent-phase plasma seemed to shorten
hospitalization without adverse effects if it is administered as an
immunotherapy to SARS patients early in the course of infection.62
With the finding that recovered SARS patients have higher and more
sustainable levels of neutralizing antibodies when compared to those
who had succumbed to the disease,63 monoclonal antibodies for pass-
ive immunization were also obtained using phage-display antibody
libraries and immortalization of B cells from convalescent SARS
patients.64,65
Although it is still not known whether naturally acquired immune
responses can confer protection from re-infection of SARS-CoV,
vaccines are likely to be the most effective way to provide protection
against a future re-emergence of SARS-CoV. Several strategies for
vaccine development included DNA vaccines, inactivated whole virus
vaccines,66,67 virus-like particles,68,69 recombinant virus vector vac-
cines,70 and recombinant protein vaccine.71 Most SARS-CoV vaccines
that elicited neutralizing antibodies are believed to be protective,
but as described, T cells may also play an important role in viral
clearance in a primary SARS-CoV infection.72,73 Zhao et al. suggested
that inefficient immune activation and a poor virus-specific T cell
response underlay severe disease in SARS-CoV infected mice.74 In
their recent report, they showed that virus-specific T cells were neces-
sary and sufficient for virus clearance and protection from clinical
disease in mouse-adapted SARS-CoV (MA15) virus-infected mice.73
In addition, CD41 T cells in a senescent mouse model were found to
play an important role in viral clearance in a primary infection with
SARS-CoV.72 In humans, SARS-CoV-specific memory T cells were
found to persist in the peripheral blood of SARS patients up to 6 years
IFNc + TNFa + IL-2
IFNc + TNFa + IL-2
IFNc / TNFa / MIP 1a
/ MIP 1b/
IFNc + MIP 1b
IFNc + MIP 1aIFNc + TNFa + IL-2 + MIP 1a
+ MIP 1 b + GM-CSF
CD4+
CD8+
Figure 1 Diagram showing the cytokine profiles of the CD41 and CD81 T cells from SARS recovered patients. The big and small arrows indicate the major and minor
populations of CD41 and CD81 T cells producing the cytokines indicated respectively.
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post-infection despite a lack of specific memory B cell response in
these patients.75 This seems to suggest that SARS- CoV-specific T cell
response could persist longer and thus indicating that cell-mediated
immune response is important for protecting against re-infection. As
all these studies suggest that T cell may play a crucial role in the
clearance of SARS-CoV, there is therefore a need for detailed char-
acterization of the T cell response to SARS-CoV for the development
of future vaccine candidates.
Finally, it is important to note that T cells can play a protective and/
or pathological role during an infection. In the case ofmouse-hepatitis
virus (MHV), an increase of morbidity and mortality in infected mice
has been associated with memory T cells.76 Although no direct evi-
dence have shown that SARS-CoV-specific T cell responses contribute
to immunopathology in SARS, it is a question that needs to be further
addressed.
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